drug
patisiran
Marketedupdated 5mo agoby $ALNY ALNYLAM PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying patisiran
- phase3APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
- EP1Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
- phase3HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
- —Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
- phase3APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
- phase3Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
- phase2Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
- phase2The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 3, 2027
364 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Aug 27, 2035compositionUS 11079379
- Aug 10, 2032compositionUS 8168775
- Nov 10, 2030formulationUS 81586014.1y
- Oct 21, 2030formulationUS 88026444.0y
- Oct 20, 2029compositionUS 102401523.0y
- Oct 20, 2029method-of-use (U-2378)US 87418663.0y
- Oct 20, 2029formulationUS 92341963.0y
- Apr 15, 2029formulationUS 111413782.5y
- Apr 15, 2029formulationUS 80580692.5y
- Apr 15, 2029formulationUS 84923592.5y
- Apr 15, 2029formulationUS 88226682.5y
- Apr 15, 2029formulationUS 93644352.5y
- Oct 3, 2027formulationUS 8642076364d
FDA exclusivities (1)
- Jan 13, 2026M-270Method (3y)
News(4)
- BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectationsBridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra.biospace · 1mo ago
- Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchiseAlnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.biospace · 2mo ago
- Alnylam plunges as earnings deliver ‘one-two punch’The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.biopharma_dive · 2mo ago
- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.fiercebiotech · 2mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that